Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (717) 717
life sciences & biomedicine (708) 708
humans (640) 640
oncology (430) 430
middle aged (425) 425
male (408) 408
female (403) 403
hematology (403) 403
aged (402) 402
adult (391) 391
aged, 80 and over (253) 253
leukemia (239) 239
treatment outcome (214) 214
biological and medical sciences (203) 203
medical sciences (203) 203
prognosis (176) 176
abridged index medicus (173) 173
adolescent (165) 165
young adult (142) 142
acute myeloid leukemia (141) 141
hematologic and hematopoietic diseases (141) 141
cancer (138) 138
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (138) 138
hemic and lymphatic diseases (130) 130
antineoplastic agents - therapeutic use (129) 129
antineoplastic combined chemotherapy protocols - therapeutic use (127) 127
chemotherapy (127) 127
hematology, oncology and palliative medicine (119) 119
care and treatment (114) 114
leukemia, myeloid, acute - drug therapy (114) 114
mutation (109) 109
research (109) 109
chronic myeloid leukemia (105) 105
disease-free survival (102) 102
tumors (97) 97
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (92) 92
retrospective studies (91) 91
survival analysis (89) 89
antineoplastic agents (88) 88
remission induction (88) 88
patients (86) 86
analysis (85) 85
myeloid leukemia (80) 80
survival rate (78) 78
protein kinase inhibitors - therapeutic use (75) 75
follow-up studies (74) 74
leukemia, myeloid, acute - genetics (71) 71
imatinib mesylate (70) 70
drug administration schedule (64) 64
myelodysplastic syndromes - drug therapy (64) 64
leukemia, myeloid, acute - mortality (63) 63
pyrimidines - therapeutic use (63) 63
drug therapy (62) 62
recurrence (62) 62
philadelphia chromosome (61) 61
survival (61) 61
pharmacology. drug treatments (60) 60
clinical trials (59) 59
myelodysplastic syndromes (59) 59
risk factors (59) 59
bone marrow (58) 58
genetic aspects (58) 58
myelodysplastic syndrome (58) 58
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (58) 58
cytarabine - administration & dosage (57) 57
tyrosine (56) 56
acute lymphoblastic leukemia (55) 55
benzamides (54) 54
antineoplastic agents - adverse effects (53) 53
antineoplastic combined chemotherapy protocols - adverse effects (53) 53
antineoplastic agents - administration & dosage (52) 52
multivariate analysis (50) 50
stem cells (49) 49
dasatinib (47) 47
health aspects (47) 47
kaplan-meier estimate (47) 47
dosage and administration (46) 46
cytogenetics (45) 45
leukemia, myeloid, acute - pathology (45) 45
neoplasms (45) 45
imatinib (43) 43
transplantation (43) 43
medical research (42) 42
myelodysplastic syndromes - mortality (42) 42
protein-tyrosine kinases - antagonists & inhibitors (42) 42
aml (41) 41
kinases (41) 41
piperazines - therapeutic use (41) 41
protein kinase inhibitors - administration & dosage (41) 41
cytarabine (40) 40
dose-response relationship, drug (40) 40
myelodysplastic syndromes - genetics (40) 40
patient outcomes (40) 40
bone marrow - pathology (39) 39
drug resistance, neoplasm (39) 39
acute lymphatic leukemia (38) 38
animals (38) 38
remission (38) 38
antineoplastic combined chemotherapy protocols - administration & dosage (37) 37
disease progression (37) 37
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. The MD Anderson manual of medical oncology
by Kantarjian, Hagop, 1952 and Koller, Charles and Wolff, Robert, 1957 and University of Texas M.D. Anderson Cancer Center
2006, ISBN 9780071414999, xviii, 1149
Neoplasms
Book
Details down arrow
2. Full Text Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
by Kantarjian, Hagop, Prof and Thomas, Deborah, MD and Jorgensen, Jeffrey, MD and Jabbour, Elias, MD and Kebriaei, Partow, MD and Rytting, Michael, MD and York, Sergernne, RN and Ravandi, Farhad, MD and Kwari, Monica, RN and Faderl, Stefan, MD and Rios, Mary Beth, RN and Cortes, Jorge, MD and Fayad, Luis, MD and Tarnai, Robert, PhD and Wang, Sa A, MD and Champlin, Richard, MD and Advani, Anjali, MD and O'Brien, Susan, MD
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 4, pp. 403 - 411
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology | United States | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Sialic Acid Binding Ig-like Lectin 2 - immunology | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antibodies, Monoclonal, Humanized - administration & dosage | Enediynes - administration & dosage | Aminoglycosides - administration & dosage | Antibodies, Monoclonal - administration & dosage | Adolescent | Survival Analysis | Aged, 80 and over | Adult | Aged | Neoplasm Staging | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Child | Viral antibodies | Oncology, Experimental | Stem cells | Monoclonal antibodies | Antibodies | Transplantation | Lymphomas | Research | Cancer | Relapse | Diseases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
by Issa, Jean-Pierre J, Prof and Roboz, Gail, Prof and Rizzieri, David, Prof and Jabbour, Elias, MD and Stock, Wendy, Prof and O'Connell, Casey, MD and Yee, Karen, MD and Tibes, Raoul, MD and Griffiths, Elizabeth A, MD and Walsh, Katherine, MD and Daver, Naval, MD and Chung, Woonbok, PhD and Naim, Sue, BS and Taverna, Pietro, PhD and Oganesian, Aram, PhD and Hao, Yong, MD and Lowder, James N, MD and Azab, Mohammad, MD and Kantarjian, Hagop, Prof
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. 1099 - 1110
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Leukemia, Myeloid, Acute - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols | Azacitidine - analogs & derivatives | Male | Dose-Response Relationship, Drug | Disease-Free Survival | Maximum Tolerated Dose | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Myelodysplastic Syndromes - pathology | Neoplasm Staging | Myelodysplastic Syndromes - drug therapy | Azacitidine - administration & dosage | Epigenetic inheritance | Safety and security measures | Molecular biology | Methylation | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
by Burger, Jan A, Dr and Keating, Michael J, Prof and Wierda, William G, Prof and Hartmann, Elena, MD and Hoellenriegel, Julia, MS and Rosin, Nathalie Y, PhD and de Weerdt, Iris, MD and Jeyakumar, Ghayathri, MD and Ferrajoli, Alessandra, MD and Cardenas-Turanzas, Marylou, PhD and Lerner, Susan, MS and Jorgensen, Jeffrey L, MD and Nogueras-González, Graciela M, MS and Zacharian, Gracy, MS and Huang, Xuelin, PhD and Kantarjian, Hagop, Prof and Garg, Naveen, MD and Rosenwald, Andreas, Prof and O'Brien, Susan, Prof
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1090 - 1099
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Male | Neoplasm Recurrence, Local - mortality | Patient Selection | Dose-Response Relationship, Drug | Aged, 80 and over | Adult | Female | Pyrazoles - adverse effects | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Rituximab | Survival Rate | Treatment Outcome | Neoplasm Recurrence, Local - diagnosis | Disease-Free Survival | Maximum Tolerated Dose | Pyrazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Antibodies, Monoclonal, Murine-Derived - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis | Antimitotic agents | Monoclonal antibodies | Safety and security measures | Antineoplastic agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015
by Thompson, Philip A., MBBS and Kantarjian, Hagop M., MD and Cortes, Jorge E., MD
Mayo Clinic proceedings, ISSN 0025-6196, 2015, Volume 90, Issue 10, pp. 1440 - 1454
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Diagnosis, Differential | Prognosis | Protein Kinase Inhibitors - classification | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Humans | Clinical Protocols | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Patient Outcome Assessment | Disease Progression | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis | Protein Kinase Inhibitors - pharmacology | Philadelphia Chromosome | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Meir Wetzler, MD
by Kurzrock, Razelle and Estrov, Zeev and Talpaz, Moshe and Kantarjian, Hagop M
Cancer, ISSN 0008-543X, 07/2015, Volume 121, Issue 13, pp. 2106 - 2107
Leukemia - therapy | Medical Oncology - history | History, 21st Century | History, 20th Century | Humans | Wetzler, Meir | Internists | Appreciation | Index Medicus | Abridged Index Medicus | Wetzler
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
by Topp, Max S, Dr and Gökbuget, Nicola, MD and Stein, Anthony S, MD and Zugmaier, Gerhard, MD and O'Brien, Susan, MD and Bargou, Ralf C, Prof and Dombret, Hervé, MD and Fielding, Adele K, PhD and Heffner, Leonard, MD and Larson, Richard A, Prof and Neumann, Svenja, MD and Foà, Robin, MD and Litzow, Mark, Prof and Ribera, Josep-Maria, Prof and Rambaldi, Alessandro, MD and Schiller, Gary, MD and Brüggemann, Monika, MD and Horst, Heinz A, MD and Holland, Chris, MS and Jia, Catherine, PhD and Maniar, Tapan, MD and Huber, Birgit, PhD and Nagorsen, Dirk, MD and Forman, Stephen J, MD and Kantarjian, Hagop M, Prof
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 57 - 66
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Recurrence | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Age Factors | United States | Humans | Middle Aged | Salvage Therapy | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Young Adult | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Time Factors | Antineoplastic Agents - adverse effects | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Antibodies, Bispecific - administration & dosage | Adult | Female | Drug Administration Schedule | Europe | Kaplan-Meier Estimate | Hematopoietic Stem Cell Transplantation | Treatment Outcome | Remission Induction | Antibodies, Bispecific - therapeutic use | Disease-Free Survival | Antibodies, Bispecific - adverse effects | Adolescent | Intention to Treat Analysis | Aged | Infusions, Intravenous | T cells | Adults | Safety and security measures | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study
by Jabbour, Elias, Dr and Kantarjian, Hagop, Prof and Ravandi, Farhad, Prof and Thomas, Deborah, Prof and Huang, Xuelin, Prof and Faderl, Stefan, Prof and Pemmaraju, Naveen, Prof and Daver, Naval, MD and Garcia-Manero, Guillermo, Prof and Sasaki, Koji, MD and Cortes, Jorge, Prof and Garris, Rebecca and Yin, C Cameron, MD and Khoury, Joseph D, MD and Jorgensen, Jeffrey, Prof and Estrov, Zeev, Prof and Bohannan, Zachary, MA and Konopleva, Marina, MD and Kadia, Tapan, MD and Jain, Nitin, MD and DiNardo, Courtney, MD and Wierda, William, Prof and Jeanis, Vicky, RN and O'Brien, Susan, Prof
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 15, pp. 1547 - 1555
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Dexamethasone - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Imidazoles - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Disease-Free Survival | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyridazines - administration & dosage | Vincristine - administration & dosage | Adult | Female | Aged | Philadelphia Chromosome | Doxorubicin - administration & dosage | Genetic research | Chemotherapy | Cancer | Heart | Tyrosine | Care and treatment | Corticosteroids | Cardiac patients | Bilirubin | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions?
by Kantarjian, Hagop, MD and Rajkumar, S. Vincent, MD
Mayo Clinic proceedings, ISSN 0025-6196, 2015, Volume 90, Issue 4, pp. 500 - 504
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Drug Costs | Health Care Sector - economics | United States | Drug Industry - economics | Humans | Antineoplastic Agents - economics | Antimitotic agents | Prices and rates | Antineoplastic agents | Analysis | Medical care, Cost of | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Meir Wetzler, MD In Memoriam
by Kurzrock, Razelle and Estrov, Zeev and Talpaz, Moshe and Kantarjian, Hagop M
Cancer, ISSN 0008-543X, 07/2015, Volume 121, Issue 13, pp. 2106 - 2107
Life Sciences & Biomedicine | Oncology | Science & Technology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study
by Takahashi, Koichi, MD and Wang, Feng, PhD and Kantarjian, Hagop, Prof and Doss, Denaha, MS and Khanna, Kanhav, MS and Thompson, Erika, MS and Zhao, Li, PhD and Patel, Keyur, MD and Neelapu, Sattva, MD and Gumbs, Curtis, BS and Bueso-Ramos, Carlos, Prof and DiNardo, Courtney D, MD and Colla, Simona, PhD and Ravandi, Farhad, Prof and Zhang, Jianhua, PhD and Huang, Xuelin, PhD and Wu, Xifeng, Prof and Samaniego, Felipe, MD and Garcia-Manero, Guillermo, Prof and Futreal, P Andrew, Prof
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 100 - 111
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Follow-Up Studies | Humans | Leukemia, Myeloid, Acute - epidemiology | Middle Aged | Male | Leukemia, Myeloid, Acute - etiology | Case-Control Studies | Incidence | Neoplasms - therapy | Adult | Female | High-Throughput Nucleotide Sequencing - methods | Texas - epidemiology | Risk Factors | Hematopoiesis - genetics | Survival Rate | Combined Modality Therapy - adverse effects | Mutation - genetics | Myelodysplastic Syndromes - epidemiology | Clone Cells - metabolism | Myelodysplastic Syndromes - etiology | Neoplasms, Second Primary - diagnosis | Neoplasms, Second Primary - epidemiology | Neoplasms, Second Primary - etiology | Myelodysplastic Syndromes - diagnosis | Clone Cells - pathology | Leukemia, Myeloid, Acute - diagnosis | Aged | Biomarkers, Tumor - genetics | Neoplasm Staging | Neoplasms - pathology | Lymphomas | Epidemiology | Leukemia | Risk factors | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights